Compare VREX & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VREX | BCYC |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 483.7M | 476.6M |
| IPO Year | N/A | 2019 |
| Metric | VREX | BCYC |
|---|---|---|
| Price | $13.93 | $6.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $16.67 | ★ $18.73 |
| AVG Volume (30 Days) | ★ 300.0K | 247.3K |
| Earning Date | 02-05-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $844,600,000.00 | $28,339,000.00 |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | $4.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.14 | N/A |
| 52 Week Low | $6.76 | $6.03 |
| 52 Week High | $15.46 | $14.95 |
| Indicator | VREX | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 75.49 | 43.09 |
| Support Level | $13.02 | $6.37 |
| Resistance Level | $13.99 | $6.88 |
| Average True Range (ATR) | 0.51 | 0.32 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 95.22 | 23.63 |
Varex Imaging Corp designs and manufactures X-ray imaging components. It operates in two segments Medical and Industrial. The Medical segment, which is the key revenue driver, designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, generators, and heat exchangers among other products. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high-voltage connectors, and coolers. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA) and the rest from the Americas and Asia Pacific region.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.